Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

ONO-4059—a Potent and Selective Reversible Bruton’s Tyrosine Kinase (Btk) Inhibitor: Single Agent, Twice Daily (BD) Dosing and Dosing with Food Results in Sustained, High Trough Levels of ONO-4059, Translating into 100% Tumour Remission in a TMD-8 Xenograft Model

Toshio Yoshizawa, Tomoko Yasuhiro, Hideyuki Honda, Kazuhito Kawabata, PhD

Blood (2014) 124 (21): 4502.

https://doi.org/10.1182/blood.V124.21.4502.4502

Published: 2014

Journal Articles

Development of an Axl/Mer Dual Inhibitor, ONO-9330547: Promising Single Agent Activity in an Acute Myeloid Leukemia (AML) Model

Tomoko Yasuhiro, Toshio Yoshizawa, Ryu Fujikawa, PhD, Kohei Tanaka, PhD, Tomoya Koike, Kazuhito Kawabata, PhD

Blood (2014) 124 (21): 999.

https://doi.org/10.1182/blood.V124.21.999.999

Published: 2014

Journal Articles

Discovery of a Novel, Potent, Selective and Injectable Small Molecule Inhibitor of Blood Coagulation Factor XIa, ONO-8610539: in Vitro and in Vivo Pharmacological Profiles

Masashi Gohda, PhD, Masaru Sakai, Kenji Tanaka, Tetsuya Hagio, PhD, Keizo Suzuki, Sho Koyama, Takehiro Ono, Ai Hashimoto, Hidekazu Matsuya, Yasushi Hirota, PhD, Takashi Kondo, PhD, Taihei Nishiyama, PhD, Akira Imagawa, Kazuhito Kawabata, PhD

Blood (2014) 124 (21): 1542.

https://doi.org/10.1182/blood.V124.21.1542.1542

Published: 2014

Journal Articles

Anti-Tumour Efficacy Study Of The Bruton’s Tyrosine Kinase (Btk) Inhibitor, ONO-4059, In Combination With The Glycoengineered Type II Anti-CD20 Monoclonal Antibody, Obinutuzumab (GA101) Demonstrates Superior In Vivo Efficacy Compared To ONO-4059 In Combination With Rituximab

Toshio Yoshizawa, PhD, Tomoko Yasuhiro, Joseph TP Birkett, PhD, Christian Klein, PhD, Kazuhito Kawabata, PhD

Blood (2013) 122 (21): 3069.

https://doi.org/10.1182/blood.V122.21.3069.3069

Published: 2013

Journal Articles

ONO-4059, A Novel Bruton’s Tyrosine Kinase (Btk) Inhibitor: Synergistic Activity In Combination With Chemotherapy In a ABC-DLBCL Cell Line

Tomoko Yasuhiro, Toshio Yoshizawa, PhD, Joseph TP Birkett, PhD, Kazuhito Kawabata, PhD

Blood (2013) 122 (21): 5151.

https://doi.org/10.1182/blood.V122.21.5151.5151

Published: 2013

Journal Articles

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma

Simon Rule, MD, Nimish Shah, MD, Gilles Andre Salles, MD, PhD, Lionel Karlin, MD, Franck Morschhauser, MD, PhD, Louis Terriou, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Claire Hutchinson, BMedSci, MRCP, FRCPath, Chris Fegan, MBBS, Guillaume Cartron, MD, PhD, Tomasz Knurowski, MD, James G Wright, PhD, Andrew J Saunders, MD, Hideyuki Honda, Bsc, Andrew Mazur, Toshio Yoshizawa, PhD, Kazuhito Kawabata, PhD, Joseph TP Birkett, PhD

Blood (2013) 122 (21): 4397.

https://doi.org/10.1182/blood.V122.21.4397.4397

Published: 2013

Journal Articles

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory and High Risk Chronic Lymphocytic Leukaemia (CLL)

Gilles Andre Salles, MD, PhD, Lionel Karlin, MD, Simon Rule, MD, Nimish Shah, MD, Franck Morschhauser, MD, PhD, Louis Terriou, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Claire Hutchinson, BMedSci, MRCP, FRCPath, Chris Fegan, MBBS, Guillaume Cartron, MD, PhD, Tomasz Knurowski, MD, Andrew J Saunders, MD, James G Wright, PhD, Hideyuki Honda, Bsc, Andrew Mazur, Toshio Yoshizawa, PhD, Kazuhito Kawabata, PhD, Joseph TP Birkett, PhD

Blood (2013) 122 (21): 676.

https://doi.org/10.1182/blood.V122.21.676.676

Published: 2013

Journal Articles

Development of a Bruton's Tyrosine Kinase (Btk) Inhibitor, ONO-WG-307: Efficacy in ABC-DLBCL Xenograft Model – Potential Treatment for B-Cell Malignancies,

Ryohei Kozaki, Toshio Yoshizawa, Shuji Tohda, MD, PhD, Tomoko Yasuhiro, Shingo Hotta, Yuko Ariza, Yoshiko Ueda, Masami Narita, Kazuhito Kawabata

Blood (2011) 118 (21): 3731.

https://doi.org/10.1182/blood.V118.21.3731.3731

Published: 2011

NARROW

ONO-4059—a Potent and Selective Reversible Bruton’s Tyrosine Kinase (Btk) Inhibitor: Single Agent, Twice Daily (BD) Dosing and Dosing with Food Results in Sustained, High Trough Levels of ONO-4059, Translating into 100% Tumour Remission in a TMD-8 Xenograft Model

Development of an Axl/Mer Dual Inhibitor, ONO-9330547: Promising Single Agent Activity in an Acute Myeloid Leukemia (AML) Model

Discovery of a Novel, Potent, Selective and Injectable Small Molecule Inhibitor of Blood Coagulation Factor XIa, ONO-8610539: in Vitro and in Vivo Pharmacological Profiles

Anti-Tumour Efficacy Study Of The Bruton’s Tyrosine Kinase (Btk) Inhibitor, ONO-4059, In Combination With The Glycoengineered Type II Anti-CD20 Monoclonal Antibody, Obinutuzumab (GA101) Demonstrates Superior In Vivo Efficacy Compared To ONO-4059 In Combination With Rituximab

ONO-4059, A Novel Bruton’s Tyrosine Kinase (Btk) Inhibitor: Synergistic Activity In Combination With Chemotherapy In a ABC-DLBCL Cell Line

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory and High Risk Chronic Lymphocytic Leukaemia (CLL)

Development of a Bruton's Tyrosine Kinase (Btk) Inhibitor, ONO-WG-307: Efficacy in ABC-DLBCL Xenograft Model – Potential Treatment for B-Cell Malignancies,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only